Asthma and COPD Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Asthma and COPD devices Market is segmented by Product (Metered Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers), Indication, and Geography.

Market Snapshot

Asthma and COPD Devices Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Global Asthma and COPD Devices market is expected to witness a CAGR of 5.2% during the forecast period. The primary factors that are driving the market growth include an increase in the burden of asthma and COPD, technological advancements, and growing geriatric population. According to World Health Organization, the number of cases of chronic obstructive pulmonary disease (COPD) has increased to 251 million cases in 2016 compared to 65 million in 2005, and rate is anticipated to grow at a notable rate over the coming years.​

The increasing geriatric population around the world expected to boost market growth. According to the United States Census Bureau’s Statistics, as of 2017, the total number of people aged between 65 years and older, surpassed 50 million. As per stated by the United Nations, during the period of 2015-2030, the number of senior persons aged 60 years or over, worldwide, is estimated to grow by 56% (from 901 million to more than 1.4 billion). Therefore, attributing to the fact that asthma is a broadly prevalent disease found in people over age 65, and asthma in older adults can cause serious health issues if not treated accurately, the rising geriatric population is expected to propel the market growth during the forecast period. However, inadequate reimbursement policiess and stringent regulatory issues are expected to hamper the asthma and COPD market growth.

Scope of the Report

Asthma is refered to as a chronic respiratory disease which blocks the airways of lung because of mucus production, inflammation, and tightening of muscles. Similarly, Chronic Obstructive Pulmonary Disease(COPD) is caused by the blockade in the airways further resulting in difficulty in breathing, owing to the primary cause as tobacco smoking. Asthma and COPD Devices are the Devices which are used to treat these afore-mentioned respiratory diseases.

By Product
Inhaler
Metered Dose Inhalers
Dry Powder Inhalers
Soft Mist Inhalers
Nebulizer
Compressor Nebulizer
Ultrasonic Nebulizer
Mesh Nebulizer
By Indication
Asthma
Chronic Obstructive Pulmonary Disease
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Asthma is Expected to Hold Largest Market Share in the Indication Type

  • A condition in which a person's airways become inflamed, narrow and swell and produce extra mucus, which makes it difficult to breathe. It is the most common chronic respiratory condition around the world.
  • Growing prevalence of asthma worldwide coupled with the activities of government organizations and NGO's in creating awareness, companies R&D activities in advancing the asthma device technologies further bolstering the segment growth.
  • For instance, in January 2019, Find Air, a European company developing digital systems for asthma and COPD control has launched it's commercial smart inhaler device FindAir ONE. This device smart add-on intended to be attached to asthma or COPD rescue medication in the form of a pMDI inhaler, that collects data about each drug usage and information about the circumstances of that use. This helps patients understand their condition and learn to predict asthma attacks.
asthma.png

North America Dominates the Market and Expected to do Same in the Forecasted Period

  • North America asthma and COPD market is anticipated to have a significant share on the global market win to the growing burden of both diseases coupled with well-established healthcare infrastructure and rising awareness.
  • According to the Centers for Disease Control and Prevention (CDC), in 2018, around 19.2 million (7.7%) adults aged 18 and over had asthma in the United States.​
  • As per the Global Asthma Network 2018 report, the economic burden of asthma increased in the United States. In 2018, annual direct costs per patient in the United States was more than USD 3,000. Due to high death rates associated with asthma and increasing investment on asthma treatment in this country, the market is expected to show significant growth in the future.
  • Moreover, the presence of key market players and advancing the product technologies further fuelling the market growth in the region.
Asthma and COPD Market - Growth Rate by Region-Image

Competitive Landscape

The global Asthma and COPD Devices market is highly competitive and consists of a few major players. Companies like AstraZeneca Plc., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Merck & Co., and Philips Healthcare, among others, hold the substantial market share in the Asthma and COPD Devices market.

Furthermore, market players involving in new product launches and collaborations. In January 2020, Apta Pharma partnered with Lupin Limited to launch India’s first connected device for metered-dose inhalers (MDI) called ADHERO. This unique add-on smart device is designed to help patients with chronic respiratory diseases such as COPD and Asthma and track their MDI usage and facilitate improved adherence to their prescribed therapy.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Incidence and Prevalence of Asthma and COPD

      2. 4.2.2 Technological Advancements

      3. 4.2.3 Growing geriatric population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Government Regulations for the Product Approval

      2. 4.3.2 Inadequate Reimbursement Policies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 Inhaler

        1. 5.1.1.1 Metered Dose Inhalers

        2. 5.1.1.2 Dry Powder Inhalers

        3. 5.1.1.3 Soft Mist Inhalers

      2. 5.1.2 Nebulizer

        1. 5.1.2.1 Compressor Nebulizer

        2. 5.1.2.2 Ultrasonic Nebulizer

        3. 5.1.2.3 Mesh Nebulizer

    2. 5.2 By Indication

      1. 5.2.1 Asthma

      2. 5.2.2 Chronic Obstructive Pulmonary Disease

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca Plc.

      2. 6.1.2 Boehringer Ingelheim GmbH

      3. 6.1.3 Drive DeVilbiss Healthcare

      4. 6.1.4 GF Health Products

      5. 6.1.5 Glaxosmithcline PLC

      6. 6.1.6 Invacare Corporation

      7. 6.1.7 Merck & Company

      8. 6.1.8 Omron Healthcare

      9. 6.1.9 PARI Pharma

      10. 6.1.10 Philips Healthcare

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asthma And Copd Devices Market market is studied from 2018 - 2026.

The Asthma And Copd Devices Market is growing at a CAGR of 5.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Philips Healthcare are the major companies operating in Asthma And Copd Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!